A Phase 1/2 interventional study of Oleclumab and Durvalumab in Carcinoma and Metastatic Pancreatic Adenocarcinoma, sponsored by MedImmune LLC. Completed at 27 sites in 4 countries. Open to participants aged 18 Years to 101 Years. Per ClinicalTrials.gov, last updated 2023-10-03.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing gemcitabine in Carcinoma — 1 open to participants now, 3 under way, 1 of them phase 3. Gemcitabine · Carcinoma.
Among the 16 studies testing gemcitabine in Carcinoma, this one is the 2nd largest by enrollment, is the only one that started in 2018, is one of 2 in phase 1/2, and was the 15th registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
Browse Carcinoma studies →1 of the 16 studies testing gemcitabine in Carcinoma is open now, in 1 country. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 101 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 3
First in 2002; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 213 is above the median of 49 across 571 interventional studies indexed under Carcinoma.
Median enrollment 44 across the 16 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
19 studies in Carcinoma by AstraZeneca: 1 open now, 11 under way, 8 of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 19 studies in Carcinoma by AstraZeneca, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2018, is the only one in phase 1/2, and was the 9th registered.
AstraZeneca’s Carcinoma studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing gemcitabine in Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 19 in Carcinoma:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.
This is a Phase 1b/2, multicenter, open-label, dose-escalation, and dose-expansion study to assess the safety, preliminary antitumor activity, immunogenicity, and pharmacokinetics (PK) of oleclumab with or without durvalumab in combination with chemotherapy administered in participants with metastatic pancreatic ductal adenocarcinoma (PDAC). Participants with previously untreated metastatic PDAC (first-line [1L] metastatic PDAC) will be enrolled in Cohort A. Participants with metastatic PDAC previously treated with gemcitabine-based chemotherapy (without exposure to 5-fluorouracil [5-FU], capecitabine, or oxaliplatin; second-line [2L] metastatic PDAC) will be enrolled in Cohort B. The study consists of 2 parts, dose escalation (Part 1) and dose expansion (Part 2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have histologically or cytologically, confirmed pancreatic adenocarcinoma:
Cohort A: Participants with previously untreated pancreatic adenocarcinoma (1L metastatic disease) not previously treated with systemic therapies Cohort B: Participants with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based chemotherapy (without exposure to 5-FU, capecitabine, oxaliplatin) 2L metastatic disease
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with 1L metastatic disease will receive intravenous (IV) infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then every 4 weeks (Q4W) in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Drug: Oleclumab · Drug: Durvalumab · Drug: Gemcitabine · Drug: Nab-paclitaxel
Participants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Drug: Oleclumab · Drug: Durvalumab · Drug: Gemcitabine · Drug: Nab-paclitaxel
Participants with 2L metastatic disease will receive IV infusions of oleclumab 1500 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m\^2 IV; folinic acid 400 mg/m\^2 IV; 5-FU 400 mg/m\^2 IV bolus followed by 2400 mg/m\^2 continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Drug: Oleclumab · Drug: Durvalumab · Drug: Oxaliplatin · Drug: Folinic acid · Drug: 5-FU
Participants with 2L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of mFOLFOX (oxaliplatin 85 mg/m\^2 IV; folinic acid 400 mg/m\^2 IV; 5-FU 400 mg/m\^2 IV bolus followed by 2400 mg/m\^2 continuous IV infusion over 46 to 48 hours) on Days 1 and 15 and then repeated on a Q4W schedule, until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Drug: Oleclumab · Drug: Durvalumab · Drug: Oxaliplatin · Drug: Folinic acid · Drug: 5-FU
Participants with 1L metastatic disease will receive IV infusions of chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Drug: Gemcitabine · Drug: Nab-paclitaxel
Participants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Drug: Oleclumab · Drug: Gemcitabine · Drug: Nab-paclitaxel
Participants with 1L metastatic disease will receive IV infusions of oleclumab 3000 mg every 2 weeks for 4 doses, then Q4W in combination with durvalumab 1500 mg Q4W plus chemotherapy of gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, both on Days 1, 8, and 15 and then repeated on Q4W schedule until disease progression, intolerable toxicity, withdrawal of participant consent, or another discontinuation criterion is met.
Drug: Oleclumab · Drug: Durvalumab · Drug: Gemcitabine · Drug: Nab-paclitaxel
Participants will receive IV infusion of oleclumab as stated in arm description.
Also known as: MEDI9447
Participants will receive IV infusion of durvalumab as stated in arm description.
Also known as: MEDI4736
Participants will receive IV infusion of gemcitabine as stated in arm description.
Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
Participants will receive IV infusion of oxaliplatin as stated in arm description.
Also known as: Modified FOLFOX (oxaliplatin, folinic acid, and 5-FU)
Participants will receive IV infusion of folinic acid as stated in arm description.
Also known as: Modified FOLFOX (oxaliplatin, folinic acid, and 5-FU)
Participants will receive IV infusion of 5-FU as stated in arm description.
Also known as: Modified FOLFOX (oxaliplatin, folinic acid, and 5-FU)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) in Dose Escalation Phase
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Time frame: Day 1 through 65.7 weeks (maximum observed duration)
Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation Phase
DLT: Any study drug related Grade (G)3 or higher toxicity including: any G4 immune-mediated AEs, \>=G3 colitis/pneumonitis/interstitial lung disease (ILD), \>=G3 nausea/vomiting/diarrhea that does not resolve to G2 or less within 3 days of maximal supportive care (MSC), G2 pneumonitis/ILD that does not resolve within 7 days of initiation of MSC, G4 anemia, G3 anemia with clinical sequelae/requires \>2 units of red blood cells transfusion, G4 thrombocytopenia/neutropenia \>=7 days, G3/4 thrombocytopenia with \>=G3 hemorrhage, G4 febrile neutropenia (FN), G3 FN lasting \>=5 days while receiving MSC, isolated G3 liver transaminase elevation (LTE)/ isolated G3 total bilirubin (TBL) that does not downgrade to G1 or less within 14 days of onset, isolated G4 LTE or TBL, elevated aspartate aminotransferase/alanine aminotransferase \>3×upper limit of normal (ULN) and concurrent TBL \>2×ULN without cholestasis or alternative explanations, any other toxicity judged as a DLT by Dose Escalation Committee.
Time frame: From Day 1 to 28 days after the first dose of study drugs
Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Escalation Phase
Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported.
Time frame: Day 1 through 65.7 weeks (maximum observed duration)
Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Dose Escalation Phase
Number of participants with abnormal ECG parameters reported as TEAEs are reported.
Time frame: Day 1 through 65.7 weeks (maximum observed duration)
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Escalation Phase
Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.
Time frame: Day 1 through 65.7 weeks (maximum observed duration)
Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose Expansion Phase
The OR is defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target lesions (TLs) and non-target lesions (NTLs), any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters (SoD) of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported.
Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Number of Participants With TEAEs and TESAEs in Dose Expansion Phase
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Time frame: Day 1 through 172.1 weeks (maximum observed duration)
Number of Participants With Abnormal Vital Signs Reported as TEAEs in Dose Expansion Phase
Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported.
Time frame: Day 1 through 172.1 weeks (maximum observed duration)
Number of Participants With Abnormal ECG Parameters Reported as TEAEs in Dose Expansion Phase
Number of participants with abnormal ECG parameters reported as TEAEs are reported.
Time frame: Day 1 through 172.1 weeks (maximum observed duration)
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs in Dose Expansion Phase
Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.
Time frame: Day 1 through 172.1 weeks (maximum observed duration)
Percentage of Participants With OR According to RECIST v1.1 in Dose Escalation Phase
The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target and non-target lesions, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters of target lesions (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported.
Time frame: Baseline (Days -28 to -1) through 24.5 months (maximum observed duration)
Percentage of Participants With Disease Control (DC) According to RECIST v1.1 in Dose Escalation Phase
The DC is defined as confirmed CR, PR, or stable disease (SD) (maintained for \>=8 weeks). The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \<10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. The SD is defined as neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for progressive disease (PD), taking as reference the smallest SoD while on study, and no new lesions. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported.
Time frame: Baseline (Days -28 to -1) through 24.5 months (maximum observed duration)
Number of Participants With Overall Survival Events in Dose Expansion Phase
The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method. The number of participants with overall survival events (deaths) is reported.
Time frame: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)
Overall Survival in Dose Expansion Phase
The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method.
Time frame: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)
Number of Participants With Progression-free Survival Events According to RECIST v1.1 in Dose Expansion Phase
Progression-free survival (PFS) is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method. The number of participants with PFS events is reported.
Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Progression-free Survival According to RECIST v1.1 in Dose Expansion Phase
The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method.
Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Duration of Response (DoR) According to RECIST v1.1 in Dose Expansion Phase
The DoR is defined as the time from the first documentation of an OR until the first documentation of a PD or death due to any cause, whichever occurs first. The OR is defined as best overall response of confirmed CR or PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. The DoR is assessed using the Kaplan-Meier method.
Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Percentage of Participants With DC According to RECIST v1.1 in Dose Expansion Phase
The DC is defined as confirmed CR, PR, or stable disease (SD) (maintained for \>=8 weeks). The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \<10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. The SD is defined as neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for PD, taking as reference the smallest SoD while on study, and no new lesions. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported.
Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Percentage of Participants With OR According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \<10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The OR is assessed by cluster of differentiation 73 (CD73) expression level either low or high at baseline. The CD73 low is defined as no CD73 expression in tumor cells or \<50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in \>=50% of tumor cells.
Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Number of Participants With Overall Survival Events by CD73 Expression at Baseline in Dose Expansion Phase
The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or \<50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in \>=50% of tumor cells. The number of participants with overall survival events (deaths) is reported.
Time frame: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)
Overall Survival by CD73 Expression at Baseline in Dose Expansion Phase
The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or \<50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in \>=50% of tumor cells.
Time frame: Baseline (Days -28 to -1) through 38.7 months (maximum observed duration)
Number of Participants With Progression-free Survival Events According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
PFS: Time from randomization until first documentation of PD/death due to any cause, whichever occurred first, regardless of whether participant received subsequent anticancer treatment prior to progression. PD:\>=20% increase in SoD of TLs and an absolute increase of \>= 5 mm of SoD/unequivocal progression of existing NTLs/appearance of new lesion. Participants who had no documented progression and were still alive at the time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/\<50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in \>=50% of tumor cells. Number of participants with PFS events is reported.
Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Progression-free Survival According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase
The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant receives subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/\<50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in \>=50% of tumor cells.
Time frame: Baseline (Days -28 to -1) through 36.1 months (maximum observed duration)
Number of Participants With Positive Anti-drug Antibodies (ADA) to Oleclumab
Number of participants with positive ADA to oleclumab are reported. Persistent positive is defined as positive at \>= 2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at \>= 2 post-baseline assessments (with \<16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration.
Time frame: Day 1 through 172.1 weeks (Pre-dose on Cycle [C] 1 Day [D] 1, C2D1, C3D1, Day 1 of every 3 cycles starting with C5, through 12 weeks post last dose of oleclumab)
Number of Participants With Positive ADA to Durvalumab
Number of participants with positive ADA to durvalumab are reported. Persistent positive is defined as positive at \>= 2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at \>= 2 post-baseline assessments (with \<16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration.
Time frame: Day 1 through 128 weeks (Pre-dose on C1D1, C2D1, C3D1, Day 1 of every 3 cycles starting with C5, through 12 weeks post last dose of durvalumab)
Serum Concentrations of Oleclumab
Serum concentrations of oleclumab are reported.
Time frame: Ten minutes (mins) (± 5 mins) post end of infusion (EOI), approximately 1 hour (+ 15 mins) after start of infusion on C1D1, C3D1, and C5D1; and pre-dose on C3D1 and C5D1
Serum Concentrations of Durvalumab
Serum concentrations of durvalumab are reported.
Time frame: Ten mins (± 5 mins) post EOI, approximately 1 hour (+ 15 mins) after start of infusion on C1D1 and C5D1; and pre-dose on C2D1 and C5D1
Plasma Concentrations of Gemcitabine and Metabolite 2',2'-Difluorodeoxyuridine (dFdU)
Plasma concentrations of gemcitabine and metabolite dFdU are reported.
Time frame: Ten mins (± 5 mins) post EOI, approximately 30-40 mins after start of infusion on C1D1 and C4D1; and pre-dose on C4D1
Plasma Concentrations of Nab-paclitaxel
Plasma concentrations of nab-paclitaxel are reported.
Time frame: Ten mins (± 5 mins) post EOI, approximately 30-40 mins after start of infusion on C1D1 and C4D1; and pre-dose on C4D1
| Milestone | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|---|---|---|---|
| Started | 7 | 7 | 3 | 8 | 62 | 38 | 70 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 7 | 3 | 8 | 62 | 38 | 70 |
| Withdrew: Death | 7 | 7 | 3 | 8 | 47 | 32 | 53 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 4 | 2 | 4 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 9 | 4 | 12 |
| Withdrew: Reasons | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
| Participants | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX |
|---|---|---|---|---|
| Any TEAEs | 7 | 7 | 3 | 8 |
| Any TESAEs | 4 | 6 | 0 | 4 |
DLT: Any study drug related Grade (G)3 or higher toxicity including: any G4 immune-mediated AEs, \>=G3 colitis/pneumonitis/interstitial lung disease (ILD), \>=G3 nausea/vomiting/diarrhea that does not resolve to G2 or less within 3 days of maximal supportive care (MSC), G2 pneumonitis/ILD that does not resolve within 7 days of initiation of MSC, G4 anemia, G3 anemia with clinical sequelae/requires \>2 units of red blood cells transfusion, G4 thrombocytopenia/neutropenia \>=7 days, G3/4 thrombocytopenia with \>=G3 hemorrhage, G4 febrile neutropenia (FN), G3 FN lasting \>=5 days while receiving MSC, isolated G3 liver transaminase elevation (LTE)/ isolated G3 total bilirubin (TBL) that does not downgrade to G1 or less within 14 days of onset, isolated G4 LTE or TBL, elevated aspartate aminotransferase/alanine aminotransferase \>3×upper limit of normal (ULN) and concurrent TBL \>2×ULN without cholestasis or alternative explanations, any other toxicity judged as a DLT by Dose Escalation Committee.
| Participants | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX |
|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) in Dose Escalation Phase | 0 | 0 | 0 | 1 |
Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported.
| Participants | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX |
|---|---|---|---|---|
| Pyrexia | 3 | 3 | 0 | 1 |
| Dyspnoea | 1 | 0 | 0 | 0 |
| Dyspnoea exertional | 0 | 1 | 0 | 0 |
| Hypotension | 2 | 1 | 0 | 1 |
| Temperature intolerance | 0 | 0 | 1 | 0 |
| Hypertension | 0 | 0 | 0 | 1 |
Number of participants with abnormal ECG parameters reported as TEAEs are reported.
| Participants | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX |
|---|---|---|---|---|
| Atrial fibrillation | 0 | 1 | 0 | 0 |
| Tachycardia | 0 | 1 | 0 | 0 |
| Atrioventricular block | 0 | 0 | 0 | 1 |
Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.
| Participants | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX |
|---|---|---|---|---|
| Anaemia | 3 | 3 | 1 | 0 |
| Neutropenia | 2 | 2 | 2 | 1 |
| Thrombocytopenia | 2 | 2 | 2 | 1 |
| Hypothyroidism | 0 | 1 | 0 | 1 |
| Alanine aminotransferase increased | 3 | 4 | 0 | 2 |
| Aspartate aminotransferase increased | 3 | 3 | 0 | 3 |
| Blood alkaline phosphatase increased | 2 | 1 | 0 | 1 |
| Blood bilirubin increased | 1 | 0 | 0 | 1 |
| Blood creatinine increased | 0 | 3 | 0 | 0 |
| Blood glucose decreased | 1 | 0 | 0 | 0 |
| International normalised ratio increased | 1 | 0 | 0 | 0 |
| Lymphocyte count decreased | 0 | 1 | 0 | 2 |
| Neutrophil count decreased | 0 | 2 | 1 | 3 |
| Platelet count decreased | 1 | 3 | 1 | 2 |
| White blood cell count decreased | 0 | 2 | 0 | 2 |
| Hypoalbuminaemia | 0 | 2 | 0 | 1 |
| Hypocalcaemia | 0 | 1 | 0 | 1 |
| Hypokalaemia | 0 | 3 | 0 | 2 |
| Hypomagnesaemia | 1 | 2 | 0 | 1 |
| Hyponatraemia | 0 | 2 | 0 | 2 |
| Hypophosphataemia | 0 | 1 | 0 | 0 |
| Proteinuria | 1 | 0 | 0 | 0 |
| Hyperthyroidism | 0 | 0 | 0 | 1 |
| Amylase increased | 0 | 0 | 1 | 1 |
| Gamma-glutamyltransferase increased | 0 | 0 | 0 | 1 |
| Lipase increased | 0 | 0 | 0 | 1 |
The OR is defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target lesions (TLs) and non-target lesions (NTLs), any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters (SoD) of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported.
| Percentage of Participants | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|
| Percentage of Participants With Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in Dose Expansion Phase | 29.0 (18.2 to 41.9) | 21.1 (9.6 to 37.3) | 32.9 (22.1 to 45.1) |
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
| Participants | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|
| Any TEAEs | 62 | 37 | 70 |
| Any TESAEs | 34 | 24 | 37 |
Number of participants with abnormal vital signs (temperature, blood pressure, pulse rate, and respiratory rate) reported as TEAEs are reported.
| Participants | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|
| Hypothermia | 0 | 0 | 1 |
| Pyrexia | 15 | 12 | 21 |
| Dyspnoea | 7 | 6 | 8 |
| Dyspnoea exertional | 1 | 1 | 2 |
| Hypertension | 2 | 3 | 11 |
| Hypotension | 3 | 4 | 4 |
| Orthostatic hypotension | 1 | 0 | 0 |
Number of participants with abnormal ECG parameters reported as TEAEs are reported.
| Participants | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|
| Supraventricular tachycardia | 0 | 1 | 0 |
| Tachycardia | 2 | 3 | 3 |
Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.
| Participants | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|
| Anaemia | 17 | 14 | 28 |
| Febrile neutropenia | 0 | 1 | 3 |
| Leukocytosis | 1 | 0 | 1 |
| Leukopenia | 1 | 2 | 3 |
| Lymphopenia | 2 | 0 | 2 |
| Neutropenia | 22 | 15 | 16 |
| Thrombocytopenia | 6 | 7 | 13 |
| Thrombocytosis | 2 | 0 | 1 |
| Hyperthyroidism | 0 | 0 | 3 |
| Hypothyroidism | 0 | 0 | 7 |
| Hypertransaminasaemia | 0 | 1 | 0 |
| Alanine aminotransferase decreased | 1 | 0 | 0 |
| Alanine aminotransferase increased | 8 | 9 | 16 |
| Amylase increased | 1 | 0 | 1 |
| Aspartate aminotransferase increased | 11 | 8 | 15 |
| Blood albumin decreased | 1 | 0 | 0 |
| Blood alkaline phosphatase increased | 3 | 2 | 8 |
| Blood bilirubin increased | 3 | 3 | 2 |
| Blood creatinine increased | 2 | 0 | 8 |
| Blood glucose increased | 0 | 2 | 0 |
| Blood lactate dehydrogenase increased | 1 | 0 | 3 |
| Blood magnesium decreased | 0 | 1 | 0 |
| Blood oestrogen decreased | 0 | 1 | 0 |
| Gamma-glutamyltransferase increased | 6 | 1 | 8 |
| Haemoglobin decreased | 0 | 0 | 1 |
| International normalised ratio increased | 0 | 0 | 1 |
| Lipase increased | 0 | 1 | 2 |
| Liver function test increased | 1 | 0 | 0 |
| Lymphocyte count decreased | 4 | 2 | 6 |
| Neutrophil count | 0 | 0 | 1 |
| Neutrophil count decreased | 19 | 8 | 24 |
| Platelet count decreased | 13 | 9 | 20 |
| Troponin I increased | 1 | 0 | 0 |
| White blood cell count decreased | 6 | 6 | 10 |
| White blood cell count increased | 0 | 1 | 0 |
| Hyperglycaemia | 4 | 2 | 6 |
| Hyperkalaemia | 1 | 1 | 1 |
| Hypoalbuminaemia | 3 | 2 | 6 |
| Hypocalcaemia | 2 | 2 | 3 |
| Hypoglycaemia | 0 | 0 | 2 |
| Hypokalaemia | 4 | 2 | 8 |
| Hypomagnesaemia | 4 | 3 | 6 |
| Hyponatraemia | 8 | 0 | 3 |
| Hypophosphataemia | 1 | 0 | 0 |
| Hypovolaemia | 1 | 0 | 0 |
| Iron deficiency | 0 | 0 | 1 |
| Type 2 diabetes mellitus | 0 | 1 | 0 |
| Proteinuria | 0 | 1 | 1 |
The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all target and non-target lesions, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the sum of the diameters of target lesions (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. Percentage of participants with OR is reported.
| Percentage of Participants | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX |
|---|---|---|---|---|
| Percentage of Participants With OR According to RECIST v1.1 in Dose Escalation Phase | 0 (NA to NA) | 14.3 (0.4 to 57.9) | 0 (NA to NA) | 12.5 (0.3 to 52.7) |
The DC is defined as confirmed CR, PR, or stable disease (SD) (maintained for \>=8 weeks). The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \<10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. The SD is defined as neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for progressive disease (PD), taking as reference the smallest SoD while on study, and no new lesions. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported.
| Percentage of Participants | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX |
|---|---|---|---|---|
| Percentage of Participants With Disease Control (DC) According to RECIST v1.1 in Dose Escalation Phase | 42.9 (9.9 to 81.6) | 71.4 (29.0 to 96.3) | 66.7 (9.4 to 99.2) | 62.5 (24.5 to 91.5) |
The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method. The number of participants with overall survival events (deaths) is reported.
| Participants with event | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|
| Number of Participants With Overall Survival Events in Dose Expansion Phase | 47 | 32 | 53 |
The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed using the Kaplan-Meier method.
| Months | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|
| Overall Survival in Dose Expansion Phase | 10.8 (8.2 to 13.2) | 8.9 (6.9 to 11.5) | 12.9 (10.1 to 15.3) |
Progression-free survival (PFS) is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method. The number of participants with PFS events is reported.
| Participants with event | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|
| Number of Participants With Progression-free Survival Events According to RECIST v1.1 in Dose Expansion Phase | 43 | 32 | 51 |
The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant received subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in sum of the diameters of target lesions, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of sum of the diameters, or unequivocal progression of existing non-target lesions, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST v1.1 assessment. The PFS is assessed using the Kaplan-Meier method.
| Months | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|
| Progression-free Survival According to RECIST v1.1 in Dose Expansion Phase | 6.7 (5.5 to 9.0) | 5.6 (3.5 to 7.5) | 7.5 (5.5 to 10.9) |
The DoR is defined as the time from the first documentation of an OR until the first documentation of a PD or death due to any cause, whichever occurs first. The OR is defined as best overall response of confirmed CR or PR based on RECIST v1.1 guidelines. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \< 10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. The DoR is assessed using the Kaplan-Meier method.
| Months | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|
| Duration of Response (DoR) According to RECIST v1.1 in Dose Expansion Phase | 7.2 (4.9 to NA) | 12.9 (2.2 to NA) | 9.5 (5.7 to 12.0) |
The DC is defined as confirmed CR, PR, or stable disease (SD) (maintained for \>=8 weeks). The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \<10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. The SD is defined as neither sufficient shrinkage of TLs to qualify for PR nor sufficient increase of TLs to qualify for PD, taking as reference the smallest SoD while on study, and no new lesions. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Percentage of participants with DC is reported.
| Percentage of Participants | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|
| Percentage of Participants With DC According to RECIST v1.1 in Dose Expansion Phase | 66.1 (53.0 to 77.7) | 73.7 (56.9 to 86.6) | 75.7 (64.0 to 85.2) |
The OR is defined as best overall response of confirmed CR or confirmed PR based on RECIST v1.1. The CR is defined as disappearance of all TLs and NTLs, any pathological lymph nodes (target and non-target) must have reduction in short axis \<10 mm, and no new lesions. The PR is defined as at least a 30% decrease in the SoD of TLs (compared to baseline) and no new lesions. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from the date of first documentation. The OR is assessed by cluster of differentiation 73 (CD73) expression level either low or high at baseline. The CD73 low is defined as no CD73 expression in tumor cells or \<50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in \>=50% of tumor cells.
| Percentage of Participants | Gemcitabine + Nab-paclitaxel: CD73 Level = High | Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High | Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High | Gemcitabine + Nab-paclitaxel: CD73 Level = Low | Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low | Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low |
|---|---|---|---|---|---|---|
| Percentage of Participants With OR According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase | 23.9 (12.6 to 38.8) | 22.2 (8.6 to 42.3) | 31.4 (19.1 to 45.9) | 43.8 (19.8 to 70.1) | 18.2 (2.3 to 51.8) | 36.8 (16.3 to 61.6) |
The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or \<50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in \>=50% of tumor cells. The number of participants with overall survival events (deaths) is reported.
| Participants with event | Gemcitabine + Nab-paclitaxel: CD73 Level = High | Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High | Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High | Gemcitabine + Nab-paclitaxel: CD73 Level = Low | Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low | Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low |
|---|---|---|---|---|---|---|
| Number of Participants With Overall Survival Events by CD73 Expression at Baseline in Dose Expansion Phase | 37 | 22 | 39 | 10 | 10 | 14 |
The overall survival is defined as the time from the randomization until death due to any cause. For participants who were alive at the time of data cut off, overall survival was censored on the last date when participants were known to be alive. The overall survival is assessed by CD73 expression level either low or high at baseline using the Kaplan-Meier method. The CD73 low is defined as no CD73 expression in tumor cells or \<50% of tumor cells with 2+ or 3+ intensity and CD73 high is defined as CD73 expression with 2+ or 3+ intensity in \>=50% of tumor cells.
| Months | Gemcitabine + Nab-paclitaxel: CD73 Level = High | Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High | Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High | Gemcitabine + Nab-paclitaxel: CD73 Level = Low | Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low | Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low |
|---|---|---|---|---|---|---|
| Overall Survival by CD73 Expression at Baseline in Dose Expansion Phase | 9.9 (6.8 to 12.2) | 7.9 (4.2 to 9.7) | 12.1 (8.6 to 15.0) | 22.2 (10.2 to 33.6) | 16.0 (5.7 to 22.6) | 16.1 (10.3 to 21.0) |
PFS: Time from randomization until first documentation of PD/death due to any cause, whichever occurred first, regardless of whether participant received subsequent anticancer treatment prior to progression. PD:\>=20% increase in SoD of TLs and an absolute increase of \>= 5 mm of SoD/unequivocal progression of existing NTLs/appearance of new lesion. Participants who had no documented progression and were still alive at the time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/\<50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in \>=50% of tumor cells. Number of participants with PFS events is reported.
| Participants with event | Gemcitabine + Nab-paclitaxel: CD73 Level = High | Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High | Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High | Gemcitabine + Nab-paclitaxel: CD73 Level = Low | Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low | Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low |
|---|---|---|---|---|---|---|
| Number of Participants With Progression-free Survival Events According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase | 35 | 23 | 39 | 8 | 9 | 12 |
The PFS is defined as the time from randomization until the first documentation of a PD or death due to any cause, whichever occurred first, regardless of whether the participant receives subsequent anticancer treatment prior to progression. The PD is defined as at least a 20% increase in SoD of TLs, taking as reference the smallest sum on study and an absolute increase of at least 5 mm of SoD, or unequivocal progression of existing NTLs, or the appearance of new lesion/s. Participants who had no documented progression and were still alive at time of analysis were censored at time of latest date of assessment from their last evaluable RECIST v1.1 assessment. PFS is assessed by CD73 expression level either low/high at baseline using Kaplan-Meier method. CD73 low: No CD73 expression in tumor cells/\<50% of tumor cells with 2+/3+ intensity. CD73 high: CD73 expression with 2+/3+ intensity in \>=50% of tumor cells.
| Months | Gemcitabine + Nab-paclitaxel: CD73 Level = High | Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = High | Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = High | Gemcitabine + Nab-paclitaxel: CD73 Level = Low | Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel: CD73 Level = Low | Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel: CD73 Level = Low |
|---|---|---|---|---|---|---|
| Progression-free Survival According to RECIST v1.1 by CD73 Expression at Baseline in Dose Expansion Phase | 5.6 (3.7 to 7.4) | 5.2 (1.9 to 6.3) | 5.5 (4.4 to 9.3) | 10.5 (6.9 to NA) | 7.6 (3.3 to 11.2) | 10.9 (5.7 to 13.2) |
Number of participants with positive ADA to oleclumab are reported. Persistent positive is defined as positive at \>= 2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at \>= 2 post-baseline assessments (with \<16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration.
| Participants | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|---|---|---|
| ADA positive at baseline | 0 | 0 | 0 | 0 | 0 | 0 |
| ADA positive post-baseline | 1 | 0 | 0 | 1 | 1 | 0 |
| Persistent Positive | 1 | 0 | 0 | 1 | 0 | 0 |
| Transient Positive | 0 | 0 | 0 | 0 | 1 | 0 |
| Treatment-boosted ADA | 0 | 0 | 0 | 0 | 0 | 0 |
Number of participants with positive ADA to durvalumab are reported. Persistent positive is defined as positive at \>= 2 post-baseline assessments (with \>=16 weeks between first and last positive) or positive at last post-baseline assessment. Transient positive is defined as negative at last post-baseline assessment and positive at only one post-baseline assessment or at \>= 2 post-baseline assessments (with \<16 weeks between first and last positive). Treatment-boosted ADA is defined as baseline ADA positive titer that was boosted to a 4-fold or higher level following drug administration.
| Participants | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|---|---|
| ADA positive at baseline | 0 | 0 | 0 | 0 | 2 |
| ADA positive post-baseline | 1 | 0 | 0 | 2 | 0 |
| Persistent Positive | 1 | 0 | 0 | 2 | 0 |
| Transient Positive | 0 | 0 | 0 | 0 | 0 |
| Treatment-boosted ADA | 0 | 0 | 0 | 0 | 0 |
Serum concentrations of oleclumab are reported.
| μg/mL | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|---|---|---|
| C1D1 (EOI) | 297.6 ± 25.70 | 710.2 ± 21.42 | 412.7 ± 11.12 | 734.6 ± 41.01 | 704.4 ± 30.28 | 725.9 ± 34.69 |
| C3D1 (pre-dose) | 128.6 ± 10.00 | 211.5 ± 73.40 | 134.3 ± 141.5 | 368.9 ± 2.461 | 164.8 ± 324.1 | 226.8 ± 70.41 |
| C3D1 (EOI) | NA ± NA | 870.3 ± 21.86 | 571.1 ± 15.75 | 1181 ± 24.97 | 893.0 ± 30.66 | 894.4 ± 39.22 |
| C5D1 (pre-dose) | NA ± NA | 73.19 ± 130.2 | — | 235.7 ± 27.68 | 85.99 ± 192.0 | 116.4 ± 54.0 |
| C5D1 (EOI) | NA ± NA | 948.3 ± 44.90 | — | 1057 ± 14.88 | 852.8 ± 24.77 | 753.2 ± 41.32 |
Serum concentrations of durvalumab are reported.
| μg/mL | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|---|---|
| C1D1 (EOI) | 292.5 ± 11.72 | 374.5 ± 27.50 | 309.0 ± 11.58 | 380.7 ± 56.89 | 345.8 ± 324.2 |
| C2D1 (pre-dose) | 35.97 ± 51.44 | 14.39 ± 5129 | 50.52 ± 57.30 | 59.97 ± 176.7 | 86.20 ± 97.95 |
| C5D1 (pre-dose) | NA ± NA | 74.52 ± 28.32 | — | 175.9 ± 43.50 | 137.9 ± 48.85 |
| C5D1 (EOI) | NA ± NA | 522.1 ± 46.72 | — | 664.5 ± 28.14 | 597.9 ± 23.40 |
Plasma concentrations of gemcitabine and metabolite dFdU are reported.
| ng/mL | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|---|---|
| Gemcitabine C1D1 (EOI) | 3194 ± 64.74 | 4659 ± 67.41 | 3301 ± 192.0 | 3315 ± 135.4 | 4086 ± 148.9 |
| Gemcitabine C4D1 (pre-dose) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Gemcitabine C4D1 (EOI) | NA ± NA | 3530 ± 48.11 | 1748 ± 236.5 | 1431 ± 446.3 | 2998 ± 151.3 |
| dFdU C1D1 (EOI) | 33700 ± 14.70 | 32160 ± 17.67 | 29510 ± 113.4 | 32350 ± 17.10 | 26300 ± 163.9 |
| dFdU C4D1 (pre-dose) | NA ± NA | 434.6 ± 344.7 | 245.1 ± 361.5 | 149.9 ± 147.0 | 177.5 ± 170.0 |
| dFdU C4D1 (EOI) | NA ± NA | 34550 ± 35.37 | 23900 ± 189.1 | 21970 ± 130.3 | 27260 ± 43.07 |
Plasma concentrations of nab-paclitaxel are reported.
| ng/mL | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|---|---|
| C1D1 (EOI) | 1711 ± 80.37 | 2685 ± 63.55 | 2381 ± 105.2 | 2711 ± 81.67 | 2611 ± 142.0 |
| C4D1 (pre-dose) | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| C4D1 (EOI) | NA ± NA | 1474 ± 96.12 | 1825 ± 178.1 | 1445 ± 145.8 | 1747 ± 99.26 |
Collected over Day 1 through 172.1 weeks (maximum observed duration). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | 7/7 (100%) | 4/7 (57.1%) | 7/7 (100%) |
| Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | 7/7 (100%) | 6/7 (85.7%) | 7/7 (100%) |
| Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | 3/3 (100%) | 0/3 (0%) | 3/3 (100%) |
| Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX | 8/8 (100%) | 4/8 (50%) | 8/8 (100%) |
| Dose-expansion, Gemcitabine + Nab-paclitaxel | 47/62 (75.8%) | 34/62 (54.8%) | 60/62 (96.8%) |
| Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | 32/38 (84.2%) | 24/38 (63.2%) | 36/38 (94.7%) |
| Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | 53/70 (75.7%) | 37/70 (52.9%) | 70/70 (100%) |
| Event | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/7 | 2/7 | 0/3 | 0/8 | 5/62 | 3/38 | 8/70 |
| PneumoniaInfections and infestations | 2/7 | 0/7 | 0/3 | 0/8 | 3/62 | 2/38 | 1/70 |
| Acute kidney injuryRenal and urinary disorders | 0/7 | 2/7 | 0/3 | 0/8 | 0/62 | 1/38 | 3/70 |
| VomitingGastrointestinal disorders | 0/7 | 2/7 | 0/3 | 1/8 | 5/62 | 0/38 | 2/70 |
| NauseaGastrointestinal disorders | 0/7 | 0/7 | 0/3 | 2/8 | 4/62 | 0/38 | 0/70 |
| CellulitisInfections and infestations | 1/7 | 0/7 | 0/3 | 0/8 | 1/62 | 2/38 | 0/70 |
| Liver abscessInfections and infestations | 0/7 | 1/7 | 0/3 | 0/8 | 0/62 | 0/38 | 0/70 |
| Atrial fibrillationCardiac disorders | 0/7 | 1/7 | 0/3 | 0/8 | 0/62 | 0/38 | 0/70 |
| SepsisInfections and infestations | 0/7 | 1/7 | 0/3 | 0/8 | 4/62 | 0/38 | 3/70 |
| Spontaneous bacterial peritonitisInfections and infestations | 0/7 | 1/7 | 0/3 | 0/8 | 0/62 | 0/38 | 0/70 |
| Event | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 6/7 | 7/7 | 2/3 | 6/8 | 30/62 | 25/38 | 41/70 |
| NauseaGastrointestinal disorders | 6/7 | 6/7 | 2/3 | 4/8 | 26/62 | 26/38 | 41/70 |
| ConstipationGastrointestinal disorders | 2/7 | 5/7 | 2/3 | 2/8 | 10/62 | 15/38 | 18/70 |
| DiarrhoeaGastrointestinal disorders | 5/7 | 2/7 | 1/3 | 5/8 | 18/62 | 14/38 | 36/70 |
| NeutropeniaBlood and lymphatic system disorders | 2/7 | 2/7 | 2/3 | 1/8 | 22/62 | 14/38 | 16/70 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/7 | 2/7 | 2/3 | 1/8 | 6/62 | 7/38 | 13/70 |
| DysgeusiaNervous system disorders | 0/7 | 3/7 | 2/3 | 0/8 | 10/62 | 5/38 | 12/70 |
| Abdominal painGastrointestinal disorders | 2/7 | 2/7 | 2/3 | 1/8 | 12/62 | 6/38 | 13/70 |
| Alanine aminotransferase increasedInvestigations | 3/7 | 4/7 | 0/3 | 2/8 | 8/62 | 9/38 | 16/70 |
| Decreased appetiteMetabolism and nutrition disorders | 4/7 | 3/7 | 1/3 | 3/8 | 16/62 | 15/38 | 21/70 |
As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received.
| Age, Continuous(Years) | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 66.7 ± 12.8 | 59.6 ± 11.4 | 67.0 ± 14.9 | 64.8 ± 4.8 | 65.6 ± 8.0 | 62.5 ± 11.1 | 62.9 ± 8.3 | 63.8 ± 9.1 |
| Sex: Female, Male(Participants) | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 3 | 4 | 1 | 4 | 26 | 17 | 34 | 89 |
| Male | 4 | 3 | 2 | 4 | 36 | 21 | 36 | 106 |
| Ethnicity (NIH/OMB)(Participants) | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 3 |
| Not Hispanic or Latino | 7 | 7 | 3 | 7 | 61 | 37 | 69 | 191 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Dose-escalation, Oleclumab 1500 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Dose-escalation, Oleclumab 1500 mg + Durvalumab + mFOLFOX | Dose-escalation, Oleclumab 3000 mg + Durvalumab + mFOLFOX | Dose-expansion, Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Gemcitabine + Nab-paclitaxel | Dose-expansion, Oleclumab 3000 mg + Durvalumab + Gemcitabine + Nab-paclitaxel | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 | 5 | 1 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 1 | 0 | 2 | 3 | 2 | 2 | 10 |
| White | 6 | 5 | 3 | 6 | 54 | 33 | 64 | 171 |
| More than one race | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jun 2018 to primary completion in Jul 2022, 49 months.
Results were first posted in Oct 2023, 1 year 2 months after primary completion.
Of 40 phase 1/2 interventional studies under Carcinoma, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 93. This study's 49 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oleclumab · Gemcitabine · Albumin-Bound Paclitaxel